• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

TIMOLOL Drug Record

  • Summary
  • Interactions
  • Claims
  • TIMOLOL chembl:CHEMBL499 Approved

    Alternate Names:

    BETIMOL
    ISTALOL
    TIMOLOL
    TIMOPTIC-XE
    NYOGEL
    BLOCADREN
    TIMOLOL HEMIHYDRATE
    TIMOPTIC
    TIOPEX
    GLAUCOL
    BETIM
    GLAU-OPT
    TIMOLOL ANHYDROUS
    (-)-S-TIMOLOL
    NYO142
    (S)-1-(TERT-BUTYLAMINO)-3-[(4-MORPHOLIN-4-YL-1,2,5-THIADIAZOL-3-YL)OXY]PROPAN-2-OL
    chemidplus:26839-75-8
    pubchem.compound:33624
    drugbank:00373
    chembl:CHEMBL499
    rxcui:1546004

    Drug Info:

    Drug Class antihypertensive agents
    Year of Approval approved before 1982
    Drug Class anti-arrhythmia agents
    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications for treatment of glaucoma
    (3 More Sources)

    Publications:

    Berman et al., 2000, The Protein Data Bank., Nucleic Acids Res.
    Ferro et al., 1997, A prospective study of the effects of prolonged timolol therapy on alpha- and beta-adrenoceptor and angiotensin II receptor mediated responses in normal subjects., Br J Clin Pharmacol
    Fuchsjager-Mayrl et al., 2005, Polymorphism of the beta-2 adrenoceptor and IOP lowering potency of topical timolol in healthy subjects., Mol. Vis.
    Borger et al., 1998, Beta-adrenoceptor-mediated inhibition of IFN-gamma, IL-3, and GM-CSF mRNA accumulation in activated human T lymphocytes is solely mediated by the beta2-adrenoceptor subtype., Am. J. Respir. Cell Mol. Biol.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Rotmensch et al., 1993, Comparisons of beta-adrenergic blocking properties of S- and R-timolol in humans., J Clin Pharmacol
    Van der Graaf et al., 1995, Exposure and characterization of the action of noradrenaline at dopamine receptors mediating endothelium-independent relaxation of rat isolated small mesenteric arteries., Br. J. Pharmacol.
    Wang et al., 1996, (--)-Timolol is a more potent antagonist of the positive inotropic effects of (--)-adrenaline than of those of (--)-noradrenaline in human atrium., Br J Clin Pharmacol
    Nieminen et al., 2005, Polymorphisms of genes CYP2D6, ADRB1 and GNAS1 in pharmacokinetics and systemic effects of ophthalmic timolol. A pilot study., Eur. J. Clin. Pharmacol.
    Bhattacharyya et al., 2002, (-)-Isoproterenol modulation of maxi-K(+) channel in nonpigmented ciliary epithelial cells through a G-protein gated pathway., Curr. Eye Res.
    Hirooka et al., 2000, Suppressive actions of betaxolol on ionic currents in retinal ganglion cells may explain its neuroprotective effects., Exp. Eye Res.
    Varma et al., 1999, Inverse agonist activities of beta-adrenoceptor antagonists in rat myocardium., Br. J. Pharmacol.
    el Tayar N et al., 1988, Modeling of beta-adrenoceptors based on molecular electrostatic potential studies of agonists and antagonists., J Med Chem
    Edeki TI et al., 1995, Pharmacogenetic explanation for excessive beta-blockade following timolol eye drops. Potential for oral-ophthalmic drug interaction., JAMA
  • TIMOLOL   ADRB1

    Interaction Score: 3.23

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction Beta-1 adrenergic receptor antagonist
    Direct Interaction yes
    Trial Name brimonidine tartrate/timolol maleate,Combigan

    PMIDs:
    8864321 16315032 12221524 11752352 10870519 10433496 2903243


    Sources:
    DTC TdgClinicalTrial ChemblInteractions TEND PharmGKB TTD

  • TIMOLOL   ADRB2

    Interaction Score: 1.61

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name brimonidine tartrate/timolol maleate,Combigan
    Novel drug target Established target
    Trial Name latanoprost + timolol,Xalcom, Xalacom

    PMIDs:
    10592235 9088585 16205624 9730867 11752352 8103526 8719802


    Sources:
    TdgClinicalTrial ChemblInteractions TEND

  • TIMOLOL   CYP2D6

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    7474246 16315032


    Sources:
    DTC PharmGKB

  • TEND: TIMOLOL

    • Version: 01-August-2011

    Alternate Names:
    TIMOLOL Primary Drug Name

    Drug Info:
    Drug Class anti-arrhythmia agents
    Year of Approval approved before 1982
    Drug Class antihypertensive agents

    Publications:

  • TdgClinicalTrial: TIMOLOL

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications for treatment of glaucoma
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • DTC: TIMOLOL

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL499 ChEMBL Drug ID

    Drug Info:

    Publications:
    el Tayar N et al., 1988, Modeling of beta-adrenoceptors based on molecular electrostatic potential studies of agonists and antagonists., J Med Chem

  • PharmGKB: timolol

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Nieminen et al., 2005, Polymorphisms of genes CYP2D6, ADRB1 and GNAS1 in pharmacokinetics and systemic effects of ophthalmic timolol. A pilot study., Eur. J. Clin. Pharmacol.
    Edeki TI et al., 1995, Pharmacogenetic explanation for excessive beta-blockade following timolol eye drops. Potential for oral-ophthalmic drug interaction., JAMA

  • TTD: Timolol

    • Version: 2020.06.01

    Alternate Names:
    D05UVD TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL499

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL499

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21